Management of cardiac disease in cancer patients throughout oncological treatment

Shirin-Haghighi MD
Associate professor of Hematology-Medical oncology
Taleghani- Hospital
Shahid- Beheshti University of medical sciences
CVD in patients with cancer is complex, and it is paramount that individual patient management and treatment is personalized.

The incorporation of surveillance strategies in cancer survivors will help prevent the potential long-term CV morbidity and mortality associated with oncological treatments.

Education of health care providers, particularly the next generation of cardiologists and haemato-oncologists, along with patients, on the importance of CV health and anticancer treatment should translate into better cancer and CV clinical outcome.
Challenges and Questions

1. Which patients with cancer are at increased risk for developing cardiac dysfunction?

2. Which preventative strategies minimize risk before initiation of therapy?

3. Which preventive strategies are effective in minimizing risk during the administration of potentially cardiotoxic cancer therapy?
Challenges and Questions

4. What are the preferred surveillance and monitoring approaches during treatment in patients at risk for cardiac dysfunction?

5. What are the preferred surveillance and monitoring approaches after treatment in patients at risk for cardiac dysfunction?
Mechanism of action and cardiovascular complication of novel anticancer agents

Management of cancer treatment related cardiovascular disease (CTRCD)

Cardiovascular complication during Covid _19 pandemic
Thank you